Subsidiary to Develop Research and Business Opportunities
Jun 18 2019 Read 243 Times
French immune-therapeutics developers Biomunex Pharmaceuticals has established a US subsidiary which will initially focus on facilitating research & development partnerships and business development activities.
“Following our recent licensing agreement with Sanofi for the generation and optimisation of bi- and multi-specific antibody therapeutics, we are excited about ramping up our R&D and partnering activities in the United States with the establishment of Biomunex Inc,” said Dr. Pierre-Emmanuel Gerard, CEO of the Paris-based parent company. “We are delighted to open our US subsidiary in Cambridge, MA, which probably represents the largest biotech cluster in the world, especially in the therapeutic antibody field. Biomunex’ ambition is to develop its product pipeline globally and this first step paves the way for US developments.”
“The establishment of the US subsidiary will contribute to our global R&D objectives by increasing discovery and development partnerships based on the BiXAb® technology with major US academic and industrial teams. Biomunex Inc will also accelerate the preclinical and clinical development of our proprietary BiXAb® antibodies,” added CSO Dr. Eugene Zhukovsky,
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - The Separation and Purification of Glutamine Deri...
View all digital editions
Nov 25 2019 Beijing, China
Dec 05 2019 New Delhi, India
Dec 13 2019 Kathmandu, Nepal
Jan 25 2020 San Diego, CA, USA
Jan 27 2020 Dubai, UAE